Survodutide achieved up to 13.1% weight loss vs 3.1% with placebo at 76 weeks in adults with obesity and T2D in the phase 3 SYNCHRONIZE-2 trial.
|Articles|October 31, 2012
Brian Carlin, MD, FCCP, Discusses Challenges in Reducing Readmission Rates
Brian Carlin, MD, FCCP, Allegheny General Hospital, discusses the challenges in reducing 30-day readmission rates, specifically as they apply to congestive heart failure, pneumonia, and COPD. The biggest challenge of all is setting up a coordinated team care effort, says Dr Carlin.
Advertisement
Brian Carlin, MD, FCCP, Allegheny General Hospital, discusses the challenges in reducing 30-day readmission rates, specifically as they apply to congestive heart failure, pneumonia, and COPD. The biggest challenge of all is setting up a coordinated team care effort, says Dr Carlin.
Advertisement
Related to this article
AASM urges CMS to reject proposed 2027 Medicare conversion factor cuts of 1.19% to 1.68% and revise sleep testing and remote monitoring policies.
A rare case of soft-tissue sarcoma spreading to the heart shows how multimodal imaging guided diagnosis and care in a 36-year-old man.
A higher ratio of red blood cell distribution width to albumin was tied to greater all-cause, cardiovascular, and cancer mortality in adults with CKD.
A meta-analysis of 22 studies found steatotic liver disease in about three-quarters of patients with sleep-disordered breathing.
FDA accepted United Therapeutics' sNDA for inhaled treprostinil in IPF. Here's what it could mean for patient access, coverage, and costs
Sustainable models require asking what a result shows, what design produced it, and whether the design was built to measure value or just produce a number.
CAR T-cell therapy must be treated as a complete "vein-to-vein" episode, with community practices needing to take control of cases for a period of time.
Advertisement
Advertisement
Trending on AJMC
1
IRA, 340B, Medicaid: The Policy Pressures on Community Oncology
2
Retatrutide Yields Up to 20.8% Weight Loss in Obesity With T2D
3
CMS Projects 16.5% Drop in 2027 Medicare Advantage Premiums
4
Drug Price Drives Value of MASH Therapies More Than Efficacy
5